Pulmonary Arterial Hypertension Specific Therapy in Patients with Combined Post- and Precapillary Pulmonary Hypertension

Table 1

Descriptive statistics of patients enrolled in the study.

Variable	Patients who tolerated PAHST			Patients who did not tolerate PAHST
	Number of patients	Mean	SE	Number of patients	Mean	SE
Age	20	64.6	2.93	6	67.4	4.61
CCI	20	3.80	0.36	6	4.0	0.37
PAPm	20	51.3	2.71	6	48.8	3.45
PAWP	20	23.6	0.84	6	27.0	2.80
TPG	20	27.7	2.53	6	21.8	2.27
PVR	19	6.5	0.78	6	7.14	2.47
DPG	20	8.3	1.65	6	4.2	2.06
CO	19	4.46	0.21	6	3.68	0.25
Vascular compromise	19	71.2	1.20	6	71.4	2.47
WHO-baseline	20	2.70	0.21	6	3.00	0.37
WHO-3 months	18	2.33	0.23
WHO-6 months	18	2.22	0.21
WHO-9 months	16	2.06	0.21
6-MWD-baseline	23	276.0	38.50	6	268.0	50.52
6-MWD-3 months	17	360.5	29.01
6-MWD-6 months	17	343.9	22.99
6-MWD-9 months	15	364.6	34.85
6-MWD (% pre)-baseline	23	56.4	6.83	6	58.3	8.99
6-MWD (% pre)-3 months	17	72.6	3.82
6-MWD (% pre)-6 months	17	72.8	3.58
6-MWD (% pre)-9 months	15	74.1	4.26
Survival (in days)	20	1350.8	173.44

PAHST = Pulmonary Arterial Hypertension Specific Therapy, CCI = Charlson Comorbidities Index, PAPm = Mean Pulmonary Artery Pressure (mmHg), PAWP = Pulmonary Arterial Wedge Pressure (mmHg), CO = Cardiac Output (L/min), TPG = Transpulmonary Gradient (mmHg), DPG = Diastolic Pressure Gradient (mmHg), PVR = Pulmonary Venous Resistance (WU), WHO = World Health Organization functional class, 6-MWD = 6-minute walk distance (meters), and SE = standard error.